These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8387051)

  • 1. Comparison of the antithrombotic effects of low molecular weight heparinoid KB-101 and heparin in a rat experimental model.
    Suehiro A; Imaoka J; Kakishita E
    Gen Pharmacol; 1993 Mar; 24(2):341-4. PubMed ID: 8387051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B; Hauptmann J; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of taurolidine on experimental thrombus formation.
    Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F
    Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and Characterization of a Heparin-Like Compound with Potent Anticoagulant and Fibrinolytic Activity from the Clam
    Du Z; Jia X; Chen J; Zhou S; Chen J; Liu X; Cao X; Zhong S; Hong P
    Mar Drugs; 2019 Dec; 18(1):. PubMed ID: 31861572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
    Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
    Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides.
    Raake W; Klauser RJ; Elling H; Meinetsberger E
    Thromb Res; 1989 Dec; 56(6):719-30. PubMed ID: 2561233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats.
    Aoki Y; Takei R; Mohri M; Gonda Y; Gomi K; Sugihara T; Kiyota T; Yamamoto S; Ishida T; Maruyama I
    Am J Hematol; 1994 Nov; 47(3):162-6. PubMed ID: 7942778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
    Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
    Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.
    Hobbelen PM; Vogel GM; Meuleman DG
    Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
    Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine.
    Racanelli A; Fareed J
    Thromb Res; 1992 Jul; 67(2):263-73. PubMed ID: 1332215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin.
    Holst J; Lindblad B; Bergqvist D; Nordfang O; Ostergaard PB; Petersen JG; Nielsen G; Hedner U
    Thromb Haemost; 1994 Feb; 71(2):214-9. PubMed ID: 8191401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity.
    Doutremepuich C; Azougagh Oualane F; Doutremepuich F; Fareed J
    Thromb Res; 1996 Aug; 83(3):217-28. PubMed ID: 8840463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic activity of a 2-kDa heparin fragment in an experimental model of carotid artery thrombosis in rats.
    Guarini S; Bazzani C; Botticelli A; Balugani A; Bertolini A
    J Pharm Pharmacol; 1996 Apr; 48(4):407-10. PubMed ID: 8794992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.